YOLFTbeta
00

Beijing Centergate Technologies Holding Co Ltd

000931 · SHE · Healthcare / Medical Instruments & Supplies

3.78CNY-0.08 (-2.07%)

Price History

Full chart

Market Stats

Previous Close3.86
Open3.85
Day Range3.77 – 3.88
52-Week Range3.76 – 5.96
Volume6.19M
Market Cap3.45B
P/E (TTM)0.00
Forward P/E84.75
EPS-0.03
Dividend Yield0.44%
Beta0.31
50-Day Avg4.48
200-Day Avg4.72

About

Beijing Centergate Technologies (holding) Co., Ltd. engages in the production and sale of topical reagents, tablets, injections in China. The company offers Anemarrhena saponin BII and capsules for vascular dementia treatment; Naltrexone Hydrochloride tablets and injections to block the pharmacological effects of exogenous opioids; Acetaminophen and oxycodone tablets and injections for the treatment of moderate to severe pain; tramadol hydrochloride tablets and injections to treat pain in adults; aprolol hydrochloride for the treatment of hypertension, angina pectoris, tachycardia-induced arrhythmia, and tremor; buspirone hydrochloride tablets to treat various anxiety disorders; oxycodone hydrochloride extended-release tablets; and Ambroxol hydrochloride injection for the treatment of acute exacerbations of chronic bronchitis, wheezing bronchitis, and bronchial asthma. It also provides Febuxostat tablets for the treatment of hyperuricemia; Bromhexine Hydrochloride injection to treat asthma, bronchiectasis, and silicosis; Metoprolol succinate raw material; Bisoprolol Amlodipine tablets for hypertension; Sitagliptin/Metformin tablets are used for type 2 diabetes patients; Bisoprolol fumarate tablets for the treatment of hypertension, coronary, and artery diseases; and Tropanestone mesylate injection for the treatment of nausea and vomiting. In addition, the company offers Sildenafil lozenges, Benzyl nonyl hydrochloride tablets, Oxycodone Hydrochloride injection, Bifonazole cream, Huperzine A tablets, Wujia Biochemical capsules, Lactobacillus tablets, Tramadol acetaminophen tablets, Tramadol hydrochloride raw material, Clindamycin phosphate to treat bacterial vaginosis, Piracetam injection, Acanthopanax senticosus, Benidipine Hydrochloride for the treatment of hypertension and angina pectoris, Glipizide Dispersible tablets, and Compound Pancreatic Enzyme powders. Beijing Centergate Technologies (holding) Co., Ltd. was founded in 1999 and is based in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Zhanjun Hou
  • Employees2.27K
  • HeadquartersBuilding B, Pengrun Building, Room 2208, Beijing, China, 100016, China
  • Websitehttps://www.centek.com.cn

Leadership

  • Mr. Zhanjun HouPresident & Non-Independent Director · b. 1972
  • Mr. Xuewu SongVP & CFO · b. 1972
  • Mr. Bin LiVice President · b. 1970
  • Ms. Xiujun FanVice President · b. 1976
  • Mr. Dehui CheVice President · b. 1970
  • Ms. Xihong WangVice President · b. 1971
  • Mr. Zhiyu HuangVP & Board Secretary · b. 1975

Financials

Income Statement

Currency: CNY1996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.81B1.75B2.10B2.22B1.57B1.91B937.61M596.50M1.32B505.77M488.81M2.23B2.06B2.33B2.60B3.31B3.27B3.61B3.03B1.08B1.48B1.74B1.77B2.14B1.79B1.96B2.06B2.28B2.53B2.44B
Growth (%)--3.70%+20.31%+5.95%-29.42%+21.48%-50.84%-36.38%+122.10%-61.82%-3.35%+356.68%-7.90%+13.30%+11.57%+27.37%-1.21%+10.23%-15.84%-64.47%+37.16%+17.73%+1.88%+20.39%-16.18%+9.29%+5.34%+10.50%+11.22%-3.52%
Cost of Revenue1.48B1.40B1.69B1.84B1.24B1.39B612.08M291.17M642.77M226.43M267.43M1.78B1.53B1.79B2.07B2.74B2.71B3.05B2.52B618.11M793.90M911.76M825.80M973.17M786.23M947.93M873.43M958.41M1.05B995.34M
Gross Profit335.51M348.05M408.97M387.07M329.02M513.35M325.54M305.32M682.05M279.35M221.38M451.66M527.19M536.55M526.90M573.01M563.94M553.26M509.23M459.92M684.67M828.95M947.71M1.16B1.00B1.01B1.19B1.32B1.48B1.45B
Gross Margin18.51%19.94%19.48%17.40%20.95%26.91%34.72%51.19%51.48%55.23%45.29%20.23%25.64%23.03%20.27%17.31%17.24%15.35%16.78%42.66%46.31%47.62%53.44%54.42%56.07%51.53%57.61%57.90%58.51%59.26%
Operating Expense188.67M253.07M281.22M208.21M124.83M426.50M524.12M691.89M599.85M797.10M240.93M465.22M438.50M483.07M504.33M565.06M499.46M729.87M468.88M277.66M648.96M773.62M851.32M936.31M853.08M991.32M1.07B1.24B1.37B1.27B
Operating Income146.84M94.98M127.75M178.86M204.18M86.85M-198.59M-386.56M82.19M-517.75M-19.55M-13.57M88.69M53.48M22.57M7.95M64.48M-176.61M40.35M182.26M35.71M55.32M96.40M225.67M150.30M16.59M117.70M78.68M111.32M176.90M
Operating Margin8.10%5.44%6.08%8.04%13.00%4.55%-21.18%-64.81%6.20%-102.37%-4.00%-0.61%4.31%2.30%0.87%0.24%1.97%-4.90%1.33%16.91%2.42%3.18%5.44%10.57%8.40%0.85%5.71%3.46%4.40%7.24%
EBITDA191.43M143.15M176.93M194.45M276.08M289.18M1.06M-370.49M260.96M-356.44M217.56M295.06M175.58M161.75M143.12M274.63M197.64M-66.81M153.79M281.18M199.33M195.22M336.22M313.96M222.44M111.91M196.13M319.75M375.02M312.51M
EBITDA Margin10.56%8.20%8.43%8.74%17.58%15.16%0.11%-62.11%19.70%-70.48%44.51%13.22%8.54%6.94%5.51%8.30%6.04%-1.85%5.07%26.08%13.48%11.22%18.96%14.70%12.43%5.72%9.52%14.04%14.81%12.79%
Net Income97.84M63.17M84.85M176.38M159.00M85.16M-188.08M-633.23M57.95M-531.28M4.19M89.02M60.53M49.92M10.46M41.64M29.89M-196.93M13.75M152.39M27.36M14.26M93.14M95.22M55.39M-100.08M-30.21M48.57M53.59M47.89M
Net Income Margin5.40%3.62%4.04%7.93%10.13%4.46%-20.06%-106.16%4.37%-105.04%0.86%3.99%2.94%2.14%0.40%1.26%0.91%-5.46%0.45%14.14%1.85%0.82%5.25%4.46%3.10%-5.12%-1.47%2.13%2.12%1.96%
R&D------------------2.74M4.18M11.37M14.98M28.02M65.51M59.24M118.71M121.54M103.50M106.06M100.68M
R&D as % of Total Revenue------------------0.09%0.39%0.77%0.86%1.58%3.07%3.31%6.07%5.90%4.55%4.19%4.12%
Interest Expense50.80M50.40M53.06M24.74M68.70M170.93M179.57M175.64M142.66M116.89M110.68M112.74M71.53M68.20M53.53M72.83M076.05M71.43M72.53M82.49M69.69M46.88M56.77M61.26M68.61M68.01M61.81M57.37M49.04M
Interest Expense % of Total Revenue2.80%2.89%2.53%1.11%4.38%8.96%19.15%29.44%10.77%23.11%22.64%5.05%3.48%2.93%2.06%2.20%0.00%2.11%2.35%6.73%5.58%4.00%2.64%2.66%3.42%3.51%3.30%2.72%2.27%2.01%

Balance Sheet

Currency: CNY1996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.35B1.45B1.35B3.12B6.60B9.69B7.40B7.46B5.72B4.85B4.45B4.71B4.02B3.81B4.01B4.33B4.20B4.35B2.51B2.76B3.15B3.65B3.53B3.58B3.46B3.70B3.54B3.78B3.71B4.00B
Total Liabilities1.01B1.05B894.21M1.50B4.48B7.38B5.37B6.10B4.53B4.18B3.79B3.80B3.22B2.95B3.14B3.54B3.37B3.71B1.82B1.90B2.08B1.86B1.63B1.73B1.54B1.88B1.87B2.04B1.91B2.15B
Total Equity344.36M395.47M459.59M1.63B1.69B1.71B1.52B901.53M1.01B499.02M511.51M614.99M624.75M691.08M702.77M732.62M761.13M563.18M628.21M790.73M881.67M1.59B1.69B1.67B1.70B1.59B1.48B1.54B1.59B1.64B
Cash54.71M90.87M202.06M395.51M876.31M1.11B434.23M180.50M344.34M520.84M208.71M164.97M82.02M157.90M231.04M146.60M229.43M537.45M133.65M216.93M177.40M453.56M377.06M252.89M206.64M170.20M121.41M191.49M151.39M139.06M
Total Debt444.59M437.00M334.07M270.91M2.43B3.08B2.43B2.22B1.57B1.43B1.22B916.87M630.10M508.27M377.28M379.65M582.06M540.40M522.24M521.40M830.92M717.21M744.53M843.41M813.72M1.01B990.04M772.82M796.97M-
Net Debt389.88M346.13M132.01M-124.60M1.55B1.97B2.00B2.04B1.23B905.91M1.01B751.90M548.08M350.38M146.24M233.05M352.64M2.95M388.60M304.47M653.53M263.65M367.47M590.52M607.08M836.46M868.63M581.33M645.58M386.45M

Cash Flow

Currency: CNY2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.29B192.03M-250.19M156.17M244.35M233.41M-79.22M720.54M196.03M186.23M183.58M243.58M-29.68M497.42M-391.31M-10.95M-32.45M158.80M205.22M164.17M200.20M263.41M183.74M218.30M127.60M41.57M
Investing Cash Flow-790.06M-504.74M-247.20M-20.76M471.57M51.43M102.76M61.78M100.30M72.18M14.78M-175.60M-8.48M-23.26M-96.02M268.63M-238.12M-146.01M-21.45M-405.43M-138.98M-88.77M-66.09M-117.47M-126.82M-
Financing Cash Flow2.56B633.36M-177.10M-388.33M-550.88M-112.97M-333.97M-900.48M-380.26M-187.94M-168.75M-124.43M66.28M-110.64M66.95M-164.91M236.64M278.69M-251.00M117.46M-110.55M-210.98M-163.64M-34.69M-47.88M-
Capital Expenditure330.44M145.74M139.58M28.51M6.84M054.21M23.29M17.71M30.84M25.12M31.38M54.38M37.18M69.57M72.90M55.85M128.24M131.71M143.62M138.31M68.53M64.29M67.32M113.42M99.89M
Free Cash Flow-1.62B46.29M-389.77M127.66M237.51M233.41M-133.43M697.25M178.33M155.39M158.46M212.20M-84.06M460.24M-460.88M-83.85M-88.30M30.56M73.51M20.55M61.89M194.88M119.46M150.98M14.18M-58.32M
Dividends Paid127.35M263.35M200.05M180.49M125.16M77.45M78.92M73.27M70.08M44.86M53.83M49.54M54.76M50.47M67.96M84.82M66.02M113.30M61.69M54.05M57.05M35.99M40.59M32.82M28.85M4.91M
FCF to OCF125.60%24.11%155.79%81.74%97.20%100.00%168.43%96.77%90.97%83.44%86.32%87.12%283.24%92.53%117.78%766.04%272.13%19.24%35.82%12.52%30.91%73.98%65.01%69.16%11.11%-140.30%
Dividend Paid to FCF-7.86%568.92%-51.33%141.39%52.70%33.18%-59.14%10.51%39.30%28.87%33.97%23.35%-65.14%10.97%-14.75%-101.16%-74.77%370.75%83.92%263.06%92.17%18.47%33.98%21.74%203.43%-8.41%

Earnings

Report DateMar 31, 2007Jun 30, 2007Sep 30, 2007Dec 31, 2007Mar 31, 2008Jun 30, 2008Sep 30, 2008Dec 31, 2008Mar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Mar 31, 2020Apr 30, 2020Aug 18, 2020Oct 27, 2020Dec 31, 2020Apr 27, 2021Aug 26, 2021Oct 28, 2021Dec 31, 2021Apr 28, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Mar 15, 2024Jun 11, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024May 9, 2025
EPS Estimate-------------------------------------------------------------------------
EPS Actual-0.04-0.03-0.040.250.02-0.000.000.070.000.020.000.05-0.010.020.04-0.02-0.010.010.07-0.01-0.020.10-0.01-0.03-0.02-0.020.01-0.27-0.04-0.020.020.06-0.030.250.02-0.02-0.020.000.030.03-0.04-0.040.050.060.010.050.07-0.010.020.070.05-0.01-0.020.040.010.00-0.010.03-0.09-0.08-0.010.010.01-0.070.010.020.020.010.020.030.020.000.02
Surprise-------------------------------------------------------------------------
Timing------------------------------------------------------------Pre-market------After-hoursAfter-hours---After-hours

Key Statistics & Ratios

Market Cap3.45B
Enterprise Value4.41B
Trailing P/E0.00
Forward P/E84.75
PEG Ratio0.00
Price / Sales1.56
Price / Book2.16
EPS-0.03
Book Value2.11
Revenue (TTM)2.21B
Gross Profit (TTM)1.17B
EBITDA201.25M
Profit Margin-0.94%
Operating Margin4.10%
Return on Equity-0.70%
Return on Assets1.44%
Shares Outstanding753.13M
Shares Float505.99M
Beta0.31
Dividend Yield0.44%
Dividend Rate0.02
Payout Ratio0.00%

Dividends

20261×
0.02Jun 12, 2026
20021×
0.09Jul 17, 2002
20011×
0.13Aug 20, 2001
20001×
0.13Jul 17, 2000

Stock Splits

  • Jan 9, 200711.6:10